Pharvaris N.V. shares fall 4.98% in after-hours after updating key study data release timeline to Q4 2025.

Pharvaris N.V. plunged 4.98% in after-hours trading, following the company's announcement that it has updated the release date for the topline data from its pivotal Phase 3 RAPIDe-3 study to the fourth quarter of 2025, with plans to submit a new drug application to the FDA in the first half of 2026, assuming positive data. The company is a late-stage biopharmaceutical company focused on developing oral therapies for rare diseases mediated by bradykinin, including deucrictibant for hereditary angioedema.